◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › E › EDIT

Editas Medicine, Inc. - (EDIT) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

NASDAQ · DATA UPDATED 2026-10-02

Editas Medicine, Inc. - (EDIT) operates in the NASDAQ industry and is headquartered in Cambridge, United States with about 87 employees. Its market capitalization is roughly $410 million. In the fiscal year ended 2025-12-31, EDIT reported $41M in revenue and ($160M) in net income.

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology.

Interactive charts & full statements → Open the EDIT valuation workbench →

EDIT Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31
Total Revenue	$48M	$41M	$32M	$78M	$20M	$26M	$91M	$21M	$32M	$14M	$6M	$2M	$0M	—
Gross Profit	$27M	$41M	($167M)	$72M	$20M	$26M	$91M	($76M)	($59M)	($69M)	($51M)	($17M)	($5M)	($2M)
Gross Margin %	56.2%	100.0%	-516.6%	92.2%	100.0%	100.0%	100.0%	-372.0%	-183.8%	-505.8%	-841.3%	-1056.9%	—	—
Operating Income (EBIT)	($83M)	($99M)	($251M)	($169M)	($226M)	($193M)	($135M)	($141M)	($114M)	($120M)	($97M)	($35M)	($13M)	($5M)
Operating Margin %	-172.9%	-245.1%	-777.2%	-216.6%	-1146.3%	-756.1%	-148.6%	-686.4%	-356.1%	-873.6%	-1605.6%	-2167.7%	—	—
Net Income	($74M)	($160M)	($237M)	($153M)	($204M)	($185M)	($109M)	($134M)	($110M)	($120M)	($97M)	($73M)	($14M)	($5M)
Net Margin %	-154.2%	-395.0%	-733.7%	-196.1%	-1036.7%	-724.7%	-120.6%	-651.4%	-344.3%	-876.5%	-1605.5%	-4475.1%	—	—
EBITDA	($70M)	($149M)	($233M)	($147M)	($220M)	($188M)	($131M)	($138M)	($110M)	($117M)	($96M)	($72M)	($13M)	($5M)
Earnings Per Share (EPS)	$-0.75	$-1.80	$-2.88	$-2.02	$-2.98	$-2.74	$-1.87	$-2.68	$-2.33	$-2.98	$-3.02	$-2.04	$-5.34	$-0.18
Shares Outstanding (M)	119M	89M	82M	76M	69M	68M	59M	50M	47M	40M	32M	—	—	30M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

EDIT Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$12M	$3M	$25M	$8M	$4M	$5M	$31M	$0M
Gross Profit	$12M	$2M	$25M	($12M)	($13M)	($22M)	($18M)	($2M)
Gross Margin %	100.0%	82.9%	100.0%	-162.2%	-352.2%	-470.9%	-58.8%	-2521.3%
Operating Income (EBIT)	($19M)	($25M)	($14M)	($25M)	($52M)	($76M)	($47M)	($66M)
Operating Margin %	-156.1%	-883.2%	-56.6%	-325.4%	-1440.6%	-1635.1%	-152.2%	-107649.2%
Net Income	($18M)	($25M)	($6M)	($25M)	($53M)	($76M)	($45M)	($62M)
Net Margin %	-153.3%	-882.4%	-22.7%	-333.0%	-1487.8%	-1633.5%	-148.3%	-101870.5%
EBITDA	($20M)	($23M)	($5M)	($22M)	($49M)	($72M)	($33M)	($61M)
Earnings Per Share (EPS)	$-0.15	$-0.26	$-0.06	$-0.28	$-0.63	$-0.92	$-0.55	$-0.75
Shares Outstanding (M)	119M	98M	89M	90M	84M	83M	83M	82M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

EDIT Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31
Cash from Operations (CFO)	($120M)	($165M)	($210M)	($132M)	($177M)	($164M)	($180M)	($41M)	($46M)	($9M)	($50M)	($5M)	($9M)	($3M)
Capital Expenditures (CapEx)	$0M	$1M	$9M	$5M	$4M	$8M	$7M	$6M	$5M	$2M	$3M	$1M	$1M	$0M
Free Cash Flow (FCF)	($120M)	($166M)	($219M)	($137M)	($181M)	($172M)	($187M)	($47M)	($50M)	($11M)	($53M)	($7M)	($10M)	($3M)
FCF Margin %	-250.0%	-409.3%	-678.1%	-175.2%	-920.6%	-672.5%	-206.1%	-228.1%	-158.0%	-83.6%	-882.5%	-419.5%	—	—
Dividends Paid	—	—	—	—	—	—	—	—	$0M	$0M	$1M	$143M	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

EDIT Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($30M)	($23M)	($36M)	($31M)	($50M)	($48M)	($51M)	($53M)
Capital Expenditures (CapEx)	$0M	$0M	$0M	$0M	$0M	$0M	$1M	$3M
Free Cash Flow (FCF)	($30M)	($23M)	($36M)	($31M)	($50M)	($48M)	($51M)	($56M)
FCF Margin %	-249.6%	-817.8%	-147.3%	-414.6%	-1403.3%	-1028.6%	-167.6%	-90998.4%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

EDIT Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31
Total Assets	$237M	$187M	$342M	$499M	$514M	$677M	$573M	$509M	$420M	$373M	$229M	$149M	$12M	$2M
Cash & Cash Equivalents	$182M	$147M	$132M	$124M	$142M	$204M	$140M	$238M	$135M	$147M	$185M	$143M	$11M	$2M
Total Liabilities	$132M	$159M	$207M	$150M	$154M	$124M	$179M	$246M	$184M	$165M	$95M	$232M	$27M	$4M
Total Debt (Short + Long-Term)	$7M	$11M	$15M	$24M	$11M	$10M	$7M	$6M	$13M	$41M	$45M	$45M	$0M	$0M
Total Shareholders' Equity	$105M	$27M	$134M	$349M	$361M	$554M	$394M	$262M	$236M	$208M	$135M	($83M)	($15M)	($2M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive EDIT viewer.

Other Companies in Software & IT Services

MASS · 908 Devices Inc. - — $465 million
ALLT · Allot Ltd. - — $428 million
BBBY · Bed Bath & Beyond, Inc. — $415 million
LWI · Lowland Ord — £411 million
GCO · Genesco Inc. — $407 million
TLS · Telos Corporation - — $405 million
CREI · Custodian Property Income REIT Ord — £402 million
CTRN · Citi Trends, Inc. - — $402 million

← EDIN All “E” companies EDIV →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.